HLS Therapeutics (TSE:HLS) Reaches New 52-Week Low – What’s Next?

Shares of HLS Therapeutics Inc. (TSE:HLS) reached a new 52-week low on Monday . The company traded as low as C$4.00 and last traded at C$4.00, with a volume of 12846 shares traded. The stock had previously closed at C$4.14.

HLS Therapeutics Stock Performance

The business’s 50-day moving average is C$4.52 and its 200-day moving average is C$4.55. The company has a market capitalization of C$137.92 million, a PE ratio of -13.78 and a beta of -0.02. The company has a debt-to-equity ratio of 75.00, a quick ratio of 1.01 and a current ratio of 1.00.

HLS Therapeutics (TSE:HLS) last announced its quarterly earnings results on Friday, May 15th. The company reported C($0.10) earnings per share (EPS) for the quarter. HLS Therapeutics had a negative return on equity of 16.54% and a negative net margin of 18.42%.The firm had revenue of C$17.88 million during the quarter. On average, research analysts anticipate that HLS Therapeutics Inc. will post -0.12 earnings per share for the current year.

About HLS Therapeutics

HLS Therapeutics Inc is a specialty pharmaceutical company. It is focused on the acquisition and commercialization of branded pharmaceutical products in the North American markets. The company is focused on treatment products for the central nervous system (CNS), and cardiovascular specialties. The company products include Clozaril, Absorica, Vascepa, CSAN Pronto, Trinomia and Perseris. The company earns revenue in the form of product sales and royalties, out of which product sales contribute to the majority of the revenue.